- Published at
- by livemint.com
mixed
mixed
Merck Narrows Sales Outlook With Gardasil Lagging in China
Merck & Co. lowered the top end of its full-year sales forecast after demand for its HPV vaccine fell for a second straight quarter in China.
News for Acceleron Pharma Inc. (XLRN)
- Published at
- by gurufocus.com
mixedmixedMerck (MRK) Lowers Sales Forecast Amid Declining HPV Vaccine Demand in China
Merck (MRK) has reduced its full-year sales guidance cap due to a second consecutive quarter of declining demand for its HPV vaccine in the Chinese market. In t- Published at
- by investing.com
mixedmixedContext Therapeutics enhances board with new appointments By Investing.com
Context Therapeutics enhances board with new appointments- Published at
- by finance.yahoo.com
mixedmixedMerck Falls as HPV Vaccine Miss Overshadows Profit, Sales Beat
(Bloomberg) -- Merck & Co.’s shares fell the most in three years as light sales of its Gardasil HPV vaccine in China dimmed quarterly profit and sales that beat Wall Street estimates.Most Read from BloombergLuxury Heir Alleges His $13 Billion Hermès Fortune Has VanishedRich Hong Kong Families Sell Mansions at Discounts to Repay DebtVenezuela’s Opposition Says It Has Proof of Election FraudTesla Analyst Nearly Crashes While Using ‘Full Self-Driving’Harris’ Running-Mate Search Zeroes In on Three T- Published at
- by globenewswire.com
mixedmixedSkye Bioscience Appoints Dr. Karen Smith to Board of Directors
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors...- Published at
- by globenewswire.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedCluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle Biopharmaceuticals, Clexio Biosciences
The dynamics of the cluster headache market are anticipated to change during the forecast period (2023–2032) owing to the rising prevalence of cluster...- Published at
- by globenewswire.com
mixedmixedTreatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis Phar
DelveInsight analysts project a favorable treatment-resistant hypertension market expansion, primarily driven by a rise in prevalence and the expected...- Published at
- by investing.com
mixedmixedEuropean Commission Expands Approval of Bristol Myers Squibb's Reblozyl ® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syn B
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl ® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syn- Published at
- by marketscreener.com
mixedmixedEuropean Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndro
Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...- Published at
- by globenewswire.com
mixedmixedHemoglobinopathy Market is Anticipated to reach US$ 1,745.7 Million by 2034: Fact.MR Report
Prominence of Personalized Medicine Approaches as a Notable Trend in the Hemoglobinopathy Market...- Published at
- by globenewswire.com
mixedmixedOcular Hypertension Market Size and Share to Increase by 2032, Asserts DelveInsight | Leading Companies in the Market- Nicox, Glaukos, AbbVie, TearClear, Ocular, Perfuse
Several approved therapies such as EYBELIS, Durysta, Alphagan-P, Rhopressa, etc. will drive the current therapeutic landscape of ocular hypertension in the...- Published at
- by financialpost.com
mixedmixedAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.- Published at
- by prnewswire.com
mixedmixedHypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B
/PRNewswire/ -- DelveInsight's Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, hypertension emerging...- Published at
- by investing.com
mixedmixedAerovate Therapeutics Appoints Habib Dable To Its Board By Investing.com
Aerovate Therapeutics Appoints Habib Dable To Its Board- Published at
- by globenewswire.com
mixedmixedHypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsight
As per a statement of World Health Organization (WHO), Hypertension is one of the silent killers in 21st century and is one of the biggest global public...- Published at
- by globenewswire.com
mixedmixedAlbireo Appoints New Members to Board of Directors
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston...- Published at
- by gurufocus.com
mixedmixedHunting Hill Global Capital, LLC Buys Kansas City Southern, Acceleron Pharma Inc, Gabelli Equity Trust Inc, Sells Willis Towers Watson PLC, ,
GuruFocus Article or News written by insider and the topic is about:- Published at
- by gurufocus.com
mixedmixedWestern Standard LLC Buys IHS Markit, Acceleron Pharma Inc, Marlin Business Services Corp, Sells , , Equity Commonwealth
GuruFocus Article or News written by insider and the topic is about:- Published at
- by gurufocus.com
positivepositiveVanguard Health Care Fund Buys
GuruFocus Article or News written by insider and the topic is about: